Capricor Therapeutics (NASDAQ:CAPR) Trading Up 7.4% – Time to Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shot up 7.4% during trading on Thursday . The stock traded as high as $20.29 and last traded at $20.3040. Approximately 644,411 shares traded hands during mid-day trading, a decline of 50% from the average session volume of 1,291,429 shares. The stock had previously closed at $18.91.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on CAPR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Roth Capital reaffirmed a “buy” rating and set a $38.00 price objective on shares of Capricor Therapeutics in a research report on Friday, May 15th. Finally, LADENBURG THALM/SH SH upgraded Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.67.

Capricor Therapeutics Trading Down 0.7%

The stock’s fifty day moving average price is $25.29 and its 200 day moving average price is $27.46. The stock has a market cap of $1.14 billion, a P/E ratio of -8.49 and a beta of 0.42.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, sell-side analysts forecast that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the transaction, the chief financial officer owned 8,223 shares of the company’s stock, valued at approximately $260,669.10. This trade represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 50,000 shares of company stock worth $1,551,658 over the last ninety days. 9.20% of the stock is currently owned by company insiders.

Institutional Trading of Capricor Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CAPR. Russell Investments Group Ltd. increased its position in Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 2,786 shares in the last quarter. ACT Capital Management LLC bought a new stake in Capricor Therapeutics in the fourth quarter worth $43,000. KBC Group NV bought a new stake in Capricor Therapeutics in the first quarter worth $44,000. Tower Research Capital LLC TRC grew its stake in shares of Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 4,976 shares during the last quarter. Finally, Regal Investment Advisors LLC purchased a new stake in shares of Capricor Therapeutics in the third quarter worth $92,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.